RxDoctor Payments Data

Jason Hume

Gerontology · Las Vegas, NVNPI 1912413956

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.7% of the total. 2025 is the largest year on record at $201, 9.1 times the $22 reported in 2022.

$435in general payments, 2019–2025

Across 19 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$112
  • Philips North America LLC$102
  • Pfizer$84
  • AstraZeneca$23
  • Novartis$23
  • Abbott$22
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$435 in reported general payments places this provider in the 60th percentile of 72 gerontology providers in Nevada.

See all gerontology providers in Nevada

Medicare billing

Part B allowed, 2024
$34,901
Medicare patients
181
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$230,879
EntrestoSacubitril/Valsartan110$132,508
JardianceEmpagliflozin61$95,574
FarxigaDapagliflozin Propanediol55$59,829
XareltoRivaroxaban16$18,757
Repatha SureclickEvolocumab18$10,976
BrilintaTicagrelor13$9,617
Metoprolol Succinate135$1,633
Atorvastatin Calcium137$1,464
Metoprolol Tartrate240$1,461
Spironolactone197$1,238
Carvedilol150$985
Amiodarone Hcl61$817
Rosuvastatin Calcium84$807
Losartan Potassium90$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$230,879176 claims
NovartisEntresto$23$132,508110 claims
AstraZenecaFarxiga, Brilinta$23$69,44668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 72 gerontology providers in Nevada.

Other gerontology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →